Comparison of LUCIO®‐direct ELISA with CEDIA immunoassay for 'zero tolerance' drug screening in urine as required by the German re‐licensing guidelines. Issue 6 (24th January 2013)

• Record Type: Journal Article
• Authors: Agius, Ronald; Nadulski, Thomas; Kahl, Hans‐Gerhard; Dufaux, Bertin
• Is Part Of: Drug testing and analysis. Volume 5:Issue 6(2013:Jun.)
• Page Start: 390
• Page End: 399
• Publication Date: 2013-01-24
• Subjects: Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.1455
• Languages: English
• ISSNs: 1942-7603

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The performance of the previously validated LUCIO®‐Direct‐enzyme linked immunosorbent assay (direct ELISA) screening tests according to forensic guidelines is compared to that of cloned enzyme donor immunoassays (CEDIA) test for drugs of abuse in urine as defined in the new re‐licensing German medical and psychological assessment (MPA) guidelines. The MPA screening cut‐offs correspond to 10 ng/ml 11‐nor‐delta‐9‐tetrahydrocannabinol‐9‐carboxylic acid (THC‐COOH), 50 ng/ml amphetamine and designer amphetamines, 25 ng/ml morphine, codeine and dihydrocodeine, 30 ng/ml benzoylecgonine, 50 ng/ml methadone metabolite, 2‐ethylidene‐1, 5‐dimethyl‐3, 3‐diphenylpyrrolidine (EDDP) and metabolites of diazepam, oxazepam, bromazepam, alprazolam, flunitrazepam and lorazepam at 50 ng/ml. Average relative sensitivities and relative specificities were 99.7 % and 98.4 % for direct ELISA and 66 % and 91.4 % for CEDIA, respectively. Copyright © 2013 John Wiley &amp; Sons, Ltd.</p> </abstract>